Understanding how a specific signaling pathway affects immune cells in acute myeloid leukemia.
The roles of AP-1 pathway activation in NK cell development and exhaustion programming in AML
This study is looking at how a specific signaling pathway affects the natural killer (NK) cells in people with acute myeloid leukemia (AML) to see if fixing this pathway can help these immune cells work better and fight the cancer more effectively.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11000766 on NIH RePORTER |
What this research studies
This research investigates the role of the AP-1 signaling pathway in the development and function of natural killer (NK) cells in patients with acute myeloid leukemia (AML). By examining the transcriptional and epigenetic changes in NK cells from AML patients, the study aims to uncover how these cells become impaired and contribute to poor patient outcomes. The researchers will explore whether inhibiting the AP-1 pathway can restore the normal function of NK cells, potentially improving their ability to fight cancer. This work involves advanced techniques to analyze cell behavior and gene expression.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute myeloid leukemia who are 21 years or older.
Not a fit: Patients with other types of leukemia or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the immune response against acute myeloid leukemia.
How similar studies have performed: Previous research has shown that targeting immune cell signaling pathways can improve cancer treatment outcomes, suggesting potential success for this approach.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Jeremy, Erin G. — Ohio State University
- Study coordinator: Jeremy, Erin G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.